Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.

UniQure shares surge as FDA aligns on accelerated approval pathway for AMT-130 in Huntington’s disease

Pallavi Madhiraju- December 10, 2024 0

UniQure, Huntington’s disease, gene therapy, FDA, accelerated approval pathway, regenerative medicine designation, AMT-130, Biologics License Application, neurodegenerative diseases, cUHDRS, Phase I/II studies, neurofilament light chain, ... Read More

Ichnos Glenmark presents data from Phase 1 study of ISB 2001 in multiple myeloma

Pallavi Madhiraju- December 10, 2024 0

In a presentation at the 66th American Society of Hematology Annual Meeting, Ichnos Glenmark Innovation (IGI) unveiled promising results from its Phase 1 clinical trial ... Read More

Cumberland Pharmaceuticals announces FDA approval for Acetadote’s simplified dosing regimen

Pallavi Madhiraju- December 10, 2024 0

Shares of Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) surged in after-hours trading following the announcement that the U.S. Food and Drug Administration (FDA) had approved a ... Read More

Paradigm Biopharmaceuticals scores A$16m investment—Here’s what it means for osteoarthritis treatment

Pallavi Madhiraju- December 9, 2024 0

Paradigm Biopharmaceuticals Ltd. (ASX: PAR) has secured a significant A$16 million in funding, positioning the company to launch its pivotal Phase 3 global clinical trial ... Read More

Actinogen Medical progresses in XanaMIA Phase 2b/3 trial for Alzheimer’s disease

Pallavi Madhiraju- December 9, 2024 0

Actinogen Medical Limited (ASX: ACW) has announced a major milestone in its ongoing XanaMIA Phase 2b/3 clinical trial, aimed at treating biomarker-positive mild to moderate ... Read More

Recce Pharmaceuticals secures approval for Phase 3 trial of R327G in Indonesia

Pallavi Madhiraju- December 9, 2024 0

Recce Pharmaceuticals Limited (ASX: RCE) has achieved a significant milestone in its quest to tackle diabetic foot infections (DFIs), a common complication among diabetes patients. ... Read More

Novartis company profile: A global leader redefining healthcare innovation

Pallavi Madhiraju- December 8, 2024 0

What is the history of Novartis and its establishment? Novartis emerged in 1996 following the merger of Ciba-Geigy and Sandoz Laboratories, two Swiss pharmaceutical leaders. ... Read More

Genmab’s epcoritamab therapy delivers promising results for relapsed follicular lymphoma

Pallavi Madhiraju- December 8, 2024 0

Relapsed or refractory follicular lymphoma (FL) remains a persistent challenge for patients, particularly those with high-risk features. Genmab A/S, alongside its development partner AbbVie, announced ... Read More

Why BioAge Labs’ promising obesity drug trial of azelaprag came to an abrupt halt

Pallavi Madhiraju- December 7, 2024 0

BioAge Labs, a clinical-stage biopharmaceutical company focused on metabolic disease research, has announced the discontinuation of its STRIDES Phase 2 obesity drug trial. The decision ... Read More

Suven Pharmaceuticals acquires majority stake in NJ Bio, strengthens US presence

Pallavi Madhiraju- December 7, 2024 0

Suven Pharmaceuticals Limited, a technology-focused contract development and manufacturing organisation (CDMO), has announced the acquisition of a controlling 56% stake in NJ Bio Inc., a ... Read More